Last reviewed · How we verify
rhTNK-tPA
At a glance
| Generic name | rhTNK-tPA |
|---|---|
| Also known as | Recombinant Human TNK Tissue-type Plasminogen Activator, Recombinant Human TNK Tissue-type Plasminogen Activator for Injection, TNKase, TNK-tPA |
| Sponsor | Beijing Tiantan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours (PHASE4)
- Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion (PHASE3)
- Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion (PHASE2, PHASE3)
- Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window (PHASE3)
- Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window. (PHASE3)
- Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window (PHASE4)
- Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5 (PHASE3)
- Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |